PTC Therapeutics - PTCT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $56.30
  • Forecasted Upside: 11.09 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$50.68
▲ +0.48 (0.96%)

This chart shows the closing price for PTCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PTC Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTCT

Analyst Price Target is $56.30
▲ +11.09% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $56.30, with a high forecast of $76.00 and a low forecast of $38.00. The average price target represents a 11.09% upside from the last price of $50.68.

This chart shows the closing price for PTCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in PTC Therapeutics. This rating has held steady since September 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2022Jefferies Financial GroupInitiated CoverageBuy$62.00Low
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$54.00Low
9/1/2022CitigroupInitiated CoverageBuy$70.00Low
8/11/2022Raymond JamesBoost TargetOutperform$55.00 ➝ $60.00Low
8/9/2022Credit Suisse GroupBoost Target$55.00Low
7/22/2022Credit Suisse GroupBoost Target$52.00Low
6/23/2022Royal Bank of CanadaBoost TargetSector Perform$42.00 ➝ $46.00Low
4/1/2022Cantor FitzgeraldReiterated RatingOverweight$64.00 ➝ $63.00N/A
2/23/2022JPMorgan Chase & Co.Boost TargetOverweight$70.00 ➝ $76.00High
2/23/2022BarclaysLower TargetEqual Weight$40.00 ➝ $39.00High
10/29/2021Raymond JamesLower TargetOutperform$70.00 ➝ $55.00High
10/29/2021Royal Bank of CanadaLower TargetSector Perform$45.00 ➝ $42.00Medium
10/29/2021Credit Suisse GroupLower TargetNeutral$50.00 ➝ $48.00High
10/18/2021Bank of AmericaDowngradeNeutral ➝ Underperform$38.00High
8/31/2021UBS GroupLower TargetNeutral$55.00 ➝ $45.00High
7/30/2021Credit Suisse GroupLower TargetNeutral$54.00 ➝ $50.00Low
6/3/2021William BlairReiterated RatingBuyHigh
5/17/2021Truist FinancialLower TargetBuy$75.00 ➝ $65.00Low
4/26/2021Credit Suisse GroupInitiated CoverageNeutral$54.00High
3/29/2021Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$47.00Medium
2/26/2021Cantor FitzgeraldLower TargetOverweight$81.00 ➝ $75.00High
2/12/2021Bank of AmericaDowngradeBuy ➝ NeutralLow
1/5/2021Smith Barney CitigroupUpgradeNeutral ➝ BuyN/A
12/16/2020Raymond JamesBoost TargetOutperform$63.00 ➝ $70.00Medium
11/30/2020Royal Bank of CanadaDowngradeSector Perform ➝ Underperform$45.00High
10/30/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralMedium
10/30/2020Cantor FitzgeraldLower TargetOverweight$75.00 ➝ $67.00High
10/28/2020UBS GroupInitiated CoverageNeutral$55.00Medium
10/7/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$71.00High
9/23/2020Raymond JamesReiterated RatingBuyMedium
8/24/2020Raymond JamesInitiated CoverageOutperform$63.00High
8/11/2020Cantor FitzgeraldLower TargetOverweight$85.00 ➝ $75.00Low
8/10/2020Bank of AmericaLower TargetBuy$60.00 ➝ $58.00Medium
8/10/2020Credit Suisse GroupLower TargetNeutral$53.00 ➝ $52.00Low
7/20/2020CowenReiterated RatingHold$50.00High
7/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$53.00High
7/20/2020SunTrust BanksBoost TargetBuy$75.00 ➝ $86.00High
5/1/2020SunTrust BanksLower TargetBuy$78.00 ➝ $75.00Medium
4/28/2020William BlairReiterated RatingBuyLow
4/9/2020CitigroupUpgradeNeutral ➝ Buy$71.00 ➝ $67.00High
4/8/2020Cantor FitzgeraldLower TargetOverweight$86.00 ➝ $85.00Medium
4/8/2020Royal Bank of CanadaReiterated RatingHold$45.00High
3/4/2020BarclaysReiterated RatingHold$51.00High
3/3/2020Cantor FitzgeraldReiterated RatingPositive ➝ Overweight$81.00 ➝ $86.00High
3/2/2020CowenReiterated RatingHoldHigh
2/20/2020CitigroupDowngradeBuy ➝ Neutral$55.00 ➝ $71.00High
2/20/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$63.00 ➝ $60.00High
2/6/2020SunTrust BanksReiterated RatingBuy$78.00Medium
2/6/2020CowenReiterated RatingHoldHigh
1/23/2020Cantor FitzgeraldBoost TargetOverweight$60.00 ➝ $81.00Low
1/15/2020Cantor FitzgeraldReiterated RatingBuy$60.00Medium
12/5/2019Royal Bank of CanadaReiterated RatingOutperform$58.00Medium
11/26/2019William BlairReiterated RatingBuyLow
11/12/2019SunTrust BanksInitiated CoverageBuy$78.00Low
10/31/2019Credit Suisse GroupReiterated RatingBuy$54.00Low
10/30/2019CowenReiterated RatingHoldHigh
9/26/2019CitigroupSet TargetBuy$62.00High
9/24/2019Royal Bank of CanadaReiterated RatingBuyHigh
8/12/2019BarclaysReiterated RatingHold$43.00Low
5/13/2019Bank of AmericaUpgradeNeutral ➝ Buy$43.00 ➝ $49.00Low
5/8/2019CowenReiterated RatingHoldHigh
5/3/2019CitigroupSet TargetBuy$59.00Low
5/2/2019CowenReiterated RatingHoldHigh
4/11/2019Sanford C. BernsteinInitiated CoverageOutperform$48.00Low
2/28/2019Cantor FitzgeraldReiterated RatingBuy$61.00High
1/29/2019Credit Suisse GroupSet TargetBuy$51.00High
1/7/2019William BlairReiterated RatingBuyHigh
1/7/2019Credit Suisse GroupReiterated RatingBuy$55.00High
1/7/2019Cantor FitzgeraldReiterated RatingBuy$61.00High
11/12/2018Cantor FitzgeraldLower TargetOverweight ➝ Overweight$66.00 ➝ $61.00High
11/6/2018Royal Bank of CanadaLower TargetOutperform ➝ Outperform$51.00 ➝ $46.00High
11/6/2018BarclaysLower TargetEqual Weight ➝ Equal Weight$43.00 ➝ $40.00High
11/6/2018William BlairReiterated RatingBuyHigh
11/5/2018Credit Suisse GroupSet TargetBuy$55.00High
10/3/2018Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
10/3/2018Credit Suisse GroupSet TargetBuy$55.00Medium
10/3/2018William BlairReiterated RatingBuyHigh
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$66.00Medium
9/28/2018JPMorgan Chase & Co.Boost TargetPositive ➝ Neutral$51.00Low
9/5/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$49.00 ➝ $53.00Low
8/8/2018BarclaysBoost TargetEqual Weight ➝ Equal Weight$40.00 ➝ $43.00High
7/31/2018Bank of AmericaBoost TargetUnderperform ➝ Underperform$27.00 ➝ $31.00High
7/24/2018CitigroupReiterated RatingBuy ➝ Buy$35.00 ➝ $50.00Low
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$49.00High
6/20/2018BarclaysUpgradeUnderweight ➝ Equal WeightHigh
6/18/2018William BlairUpgradeMarket Perform ➝ OutperformHigh
6/18/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$11.00High
5/10/2018William BlairReiterated RatingHoldHigh
4/3/2018BarclaysDowngradeEqual Weight ➝ Underweight$24.00 ➝ $26.00High
3/7/2018BarclaysReiterated RatingEqual Weight ➝ Equal Weight$18.00 ➝ $24.00High
3/7/2018William BlairReiterated RatingHoldHigh
2/21/2018CitigroupBoost TargetBuy ➝ Buy$24.00 ➝ $35.00High
1/30/2018Credit Suisse GroupReiterated RatingBuy$28.00Medium
1/29/2018Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector PerformHigh
1/23/2018BarclaysReiterated RatingHoldLow
11/24/2017JPMorgan Chase & Co.Boost TargetUnderweight ➝ Neutral$15.00N/A
11/16/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$15.00N/A
10/26/2017Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
10/25/2017CowenReiterated RatingHoldN/A
10/25/2017Royal Bank of CanadaSet TargetHold$15.00N/A
10/9/2017JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$23.00 ➝ $15.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/6/2022
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/5/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/3/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/3/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
PTC Therapeutics logo
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Read More

Today's Range

Now: $50.68
Low: $49.40
High: $51.14

50 Day Range

MA: $50.62
Low: $43.25
High: $53.85

52 Week Range

Now: $50.68
Low: $25.01
High: $55.58

Volume

568,593 shs

Average Volume

601,583 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for PTCT.

What is the current price target for PTC Therapeutics?

10 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $56.30, suggesting a possible upside of 11.1%. JPMorgan Chase & Co. has the highest price target set, predicting PTCT will reach $76.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $38.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.

What is the current consensus analyst rating for PTC Therapeutics?

PTC Therapeutics currently has 1 sell rating, 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PTCT, but not buy more shares or sell existing shares.
View the latest ratings for PTCT.

What other companies compete with PTC Therapeutics?

How do I contact PTC Therapeutics' investor relations team?

PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is (908) 222-7000 and its investor relations email address is [email protected] The official website for PTC Therapeutics is www.ptcbio.com. Learn More about contacing PTC Therapeutics investor relations.